Frequently Asked Questions

Curasight is a Copenhagen-based clinical-stage radiopharmaceutical company developing uPAR-targeted imaging, diagnostic and radioligand therapy products. The company is listed on Spotlight Stock Market under ticker CURAS.

uPAR is the urokinase-type plasminogen activator receptor, a cell-surface receptor associated with tumor invasion, angiogenesis and metastasis. Curasight targets uPAR with peptide-based radiopharmaceuticals.

None of the product candidates within the uTREAT® or uTRACE® platforms are currently approved for commercial use (marketing authorization). The relevant product candidates are investigational.

uTREAT® is Curasight’s uPAR-targeted therapeutic development platform. It can encompass multiple ligands and distinct radionuclide-specific product candidates, including imaging and dosimetry constructs used specifically to enable therapeutic development. In the glioblastoma program, the current Phase 1 study uses 64Cu-DOTA-AE105 at imaging and dosimetry activity within uTREAT®, while a separate 177Lu product is intended for therapeutic dosing.

uTRACE® is Curasight’s uPAR-targeted imaging and diagnostic platform. Individual imaging agents within the platform are defined by their specific ligand, chelator, radionuclide and intended use. The accumulated uTRACE® evidence supports the broader uPAR strategy. The prostate cancer indication currently in phase 2 is licensed to Curium.

They share the same biological target, uPAR, and can draw on related ligand chemistry and human imaging evidence, but they are separate platforms. uTRACE® includes imaging and diagnostic agents, while uTREAT® includes therapeutic product candidates. A clinical program may use a uTRACE® imaging agent to inform development of a uTREAT® therapeutic product, but that does not make the products identical or require one-to-one pairing. uTRACE® will also be used as a target confirmation tool for selection of patients suited for uTREAT® therapy.

Glioblastoma is an aggressive cancer with high unmet need and published human imaging evidence showing uPAR-positive disease in grade 4 gliomas. Within the uTREAT® program, Curasight is using regional super-selective intra-arterial administration (SIACI) of 64Cu-DOTA-AE105 at imaging and dosimetry activity to measure tumor delivery, biodistribution and dosimetry before therapeutic dosing is introduced through a separate 177Lu product in a subsequent study.

Within the uTREAT® platform, Curasight is advancing a next-generation uPAR-targeting ligand for systemic radioligand therapy. The ligand architecture is designed to support separate radionuclide-specific (alpha or beta emitters) product candidates, where biology and dosimetry support them. Candidate selection is based on binding, stability, biodistribution, dosimetry and manufacturability.

Curasight A/S is listed on Spotlight Stock Market under ticker CURAS.

Material company developments are published through Curasight’s press releases and investor pages. Investors should rely on the latest published market disclosures and financial reports.